What Can We Help You Find?

Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

10/4
2019

RET Drug Shrinks Tumors in Trial

From Reuters Eli Lilly and Co’s LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carrie…

10/4
2019

I/O Imfinzi prolongs survival

From Reuters AstraZeneca’s cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against riv…

09/24
2019

TMB and Lung Cancer Treatment

From Fierce Pharma Looking to find their niche in the ultra-lucrative non-small cell lung cancer market, some immuno-oncology companies have turned to investigational biomarker TMB, or tumor mutational burden, in hopes of ID’ing patie…

09/24
2019

KRAS Treatment Shows Promise

Potentially First Approved KRAS Treatment From Reuters: An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, ear…

09/4
2019

Entrectinib approved for ROS1 and NTRK

From Drugs.com: FDA Approves Entrectinib for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors Entrectinib approval Genentech, a member of the Roche Group, today announced…

09/4
2019

Liquid Biopsy: Are We Ready for a ‘Blood-First’ Approach?

From: IASLC Lung Cancer News Although the discovery of liquid biopsy testing looks to be a promising, non-invasive test to determine a patient's biomarkers, it hasn't been adopted into the mainstream quite yet. Targeted therapy has …

08/9
2019

Long-Term Survival for EGFR+

From Targeted Oncology Sequential afatinib (Gilotrif) followed by osimertinib (Tagrisso) has demonstrated a long-term overall survival (OS) of close to 4 years in patients with non–small cell lung cancer (NSCLC) who have EGFR&nbs…

07/24
2019

Blood Test Could Identify Potential Lung Cancer Markers

From Massachusetts General Hospital Blood test to ID lung cancer By examining both blood samples and tumor tissues from patients with non-small-cell lung cancer (NSCLC), investigators at Massachusetts General Hospital (MGH) have iden…

07/3
2019

Clinical Trial Navigators

From The New York Times Fewer than 5 percent of cancer patients participate in research that could improve care. Clinical Trial Navigators could help patients find the right studies. Since a Phase I trial has prolonged my life for al…

06/26
2019

FDA approves Keytruda for SCLC

FDA approves Keytruda The FDA approved pembrolizumab monotherapy for patients with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy and at least one other prior line of therapy. This marks…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson